Vol. 147 No. 1920 (2017)
Severe injection site reactions after subcutaneous administration of Sayana®: a retrospective, post-marketing analysis of WHO and Swiss spontaneous pharmacovigilance reports
Sayana® was introduced as the first depot medroxyprogesterone acetate-containing contraceptive that is administered via subcutaneous injection. Within 10 months, the Regional Pharmacovigilance Centre (RPVC) Zurich received several anonymous reports of serious local reactions after Sayana® administration. In this retrospective study, individual case safety reports (ICSRs) on local adverse drug reactions (ADRs) related to Sayana® were analysed from the WHO pharmacovigilance database.
International, national and regional ICSRs during Sayana® administration up to 1 January 2016 were examined. Data on ADRs were retrieved from the WHO Global Database VigiBase™. Demographic data, drug administration information, duration of Sayana® treatment, latency time of the ADR, and its course, severity and outcomes were analysed.
Worldwide, 398 ICSRs after Sayana® use were registered in the database. We identified 20 reported terms that were potentially used to describe a persistent lipodystrophy. When only cases containing one or more of these 20 reported terms were selected, 323 (81.2%) international ICSRs remained for analysis. Of those, 91.6% (n = 296) were categorised as serious. The majority of the reactions (n = 193, 54.4%) did not recover. In the 67 Swiss ICSRs, 77 ADRs were reported using 10 different terms including severe or persistent local reactions like lipodystrophy, atrophy or fat necrosis. Thirty-two patients (47.7%) did not recover. All 11 regional cases reported to the RPVC Zurich were categorised as serious ADRs. For the majority of the patients (n = 7, 63.6%) the interval between the application of Sayana® and development of the lipodystrophy was between 2 and 4 months. Most of the reactions were irreversible (n = 9, 81.8%). One patient underwent plastic surgery for artificial infill of the dent.
Persistent local injection site reactions such as lipodystrophy, fat tissue necrosis or atrophy occur frequently after subcutaneous Sayana® use. These adverse drug reactions were recently integrated in the Swiss product information. Physicians and patients should be informed and advised about these potentially irreversible effects.
- Royer PA, Jones KP. Progestins for contraception: modern delivery systems and novel formulations. Clin Obstet Gynecol. 2014;57(4):644–58. https://doi.org/10.1097/GRF.0000000000000072
- Product Information Sayana©, Pfizer AG, available from www.swissmedicinfo.ch, [updated Oct. 2014, accessed 2015-09-16].
- Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception. 2016;94(3):202–15. https://doi.org/10.1016/j.contraception.2016.02.003
- Swissmedic. Arzneimittel Statistik. Swissmedic Journal. 2012;4:347.
- Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception. 2012;85(5):458–64. https://doi.org/10.1016/j.contraception.2011.10.002
- Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception. 2012;85(5):453–7. https://doi.org/10.1016/j.contraception.2011.09.015
- Uppsala Monitoring Centre. VigiLyze. https://vigilyze.who-umc.org/. (accessed 2016-01-01).
- Swissmedic [Internet]. Market Surveillance, Pharmacovigilance. Available from https://www.swissmedic.ch/marktueberwachung/00135/00160/index.html?lang=en (accessed 2016-05-29).
- Micromedex® (Healthcare Series), (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/ (accessed 2015-09-16).
- Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269–75. https://doi.org/10.1016/j.contraception.2004.06.011
- Product Information Depo-Provera© 150, Pfizer AG [Internet], available from www.swissmedicinfo.ch, [updated Oct. 2014, accessed 2016-05-29].
- Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7–17. https://doi.org/10.1016/j.contraception.2009.02.005
- Dorai V, Hazard MC, Paris J, Delansorne R. Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro. J Pharmacol Exp Ther. 1991;258(2):620–5.
- Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96. https://doi.org/10.2165/00002018-200629050-00003